Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-miniCHOP + acalabrutinib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
R-miniCHOP + acalabrutinib is a combination therapy used in the treatment of diffuse large B-cell lymphoma (DLBCL), particularly in older or frail adults. R-miniCHOP is an attenuated version of the standard CHOP chemotherapy regimen and includes rituximab (a monoclonal antibody targeting CD20), cyclophosphamide, doxorubicin, vincristine, and prednisolone. Acalabrutinib is a highly selective, covalent small molecule inhibitor of Bruton tyrosine kinase (BTK), which plays a critical role in B-cell receptor signaling. The addition of acalabrutinib to R-miniCHOP aims to improve outcomes by further inhibiting malignant B-cell proliferation and survival. Clinical trials have shown that this combination results in increased but manageable toxicity without an increased rate of treatment-emergent deaths[1][3][8]. The regimen is under investigation for its potential to prolong progression-free survival in untreated DLBCL patients who are not candidates for full-dose chemotherapy.
- Brand names
- CalquenceRituxanMabThera
- Other names
- miniCHOP + rituximab + acalabrutinibattenuated CHOP + rituximab + acalabrutinib
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on R-miniCHOP + acalabrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-miniCHOP + acalabrutinib.